Comparison of fondaparinux and enoxaparin in acute coronary syndromes

The New England Journal of Medicine
Fifth Organization to Assess Strategies in Acute Ischemic Syndromes InvestigatorsKeith A A Fox

Abstract

The combined use of anticoagulants, antiplatelet agents, and invasive coronary procedures reduces ischemic coronary events but also increases bleeding in patients with acute coronary syndromes. We therefore assessed whether fondaparinux would preserve the anti-ischemic benefits of enoxaparin while reducing bleeding. We randomly assigned 20,078 patients with acute coronary syndromes to receive either fondaparinux (2.5 mg daily) or enoxaparin (1 mg per kilogram of body weight twice daily) for a mean of six days and evaluated death, myocardial infarction, or refractory ischemia at nine days (the primary outcome); major bleeding; and their combination. Patients were followed for up to six months. The number of patients with primary-outcome events was similar in the two groups (579 with fondaparinux [5.8 percent] vs. 573 with enoxaparin [5.7 percent]; hazard ratio in the fondaparinux group, 1.01; 95 percent confidence interval, 0.90 to 1.13), satisfying the noninferiority criteria. The number of events meeting this combined outcome showed a nonsignificant trend toward a lower value in the fondaparinux group at 30 days (805 vs. 864, P=0.13) and at the end of the study (1222 vs. 1308, P=0.06). The rate of major bleeding at nine days w...Continue Reading

Associated Clinical Trials

References

Feb 7, 2001·Chest·J I Weitz, J Hirsh
Aug 25, 2001·The New England Journal of Medicine·S YusufUNKNOWN Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Feb 7, 2002·Lancet·UNKNOWN Direct Thrombin Inhibitor Trialists' Collaborative Group
Feb 20, 2002·Controlled Clinical Trials·Brian L Wiens
Oct 31, 2003·The New England Journal of Medicine·H R BüllerUNKNOWN Matisse Investigators
Jun 3, 2004·Annals of Internal Medicine·Harry R BüllerUNKNOWN Matisse Investigators
Jun 15, 2004·Journal of the American College of Cardiology·Maarten L SimoonsUNKNOWN PENTUA Investigators
Oct 7, 2004·JAMA : the Journal of the American Medical Association·Sunil V RaoRobert M Califf
Mar 15, 2005·European Heart Journal·Pedro de Araújo GonçalvesRicardo Seabra-Gomes
Jun 16, 2005·JAMA : the Journal of the American Medical Association·Shamir R MehtaSalim Yusuf

❮ Previous
Next ❯

Citations

Sep 29, 2009·Herz·Alexander BufeStéphanie Briswalter
Feb 14, 2009·Herz·Helge MöllmannChristian W Hamm
Dec 25, 2009·Cardiovascular Drugs and Therapy·Elias B HannaJorge F Saucedo
Aug 18, 2010·Cardiovascular Drugs and Therapy·Nicolas Danchin, Nadia Aïssaoui
Mar 22, 2012·Cardiovascular Drugs and Therapy·Newton B WigginsJohn H Alexander
Jan 16, 2007·Journal of Thrombosis and Thrombolysis·Jonathan D RichChristopher P Cannon
Nov 2, 2007·Journal of Thrombosis and Thrombolysis·Steven R SteinhublRichard C Becker
Oct 3, 2008·Journal of Thrombosis and Thrombolysis·Qian-Ping GaoLu Fu
Jul 14, 2009·Journal of Thrombosis and Thrombolysis·Bina AhmedHarold L Dauerman
Jan 22, 2010·Journal of Thrombosis and Thrombolysis·S Michael GharacholouJohn H Alexander
May 14, 2010·Journal of Thrombosis and Thrombolysis·Matthew A Cavender, Sunil V Rao
Aug 17, 2010·Journal of Thrombosis and Thrombolysis·Richard C Becker
Sep 22, 2010·Journal of General Internal Medicine·Esteban Walker, Amy S Nowacki
Sep 16, 2010·Current Treatment Options in Cardiovascular Medicine·Marc Bonaca, Robert P Giugliano
Oct 22, 2011·Current Treatment Options in Cardiovascular Medicine·Davide Capodanno, Dominick J Angiolillo
Oct 23, 2012·Current Treatment Options in Cardiovascular Medicine·Charles V Pollack
Oct 20, 2009·International Journal of Hematology·Zuzana KudrnováRadka Brzežková
Dec 14, 2011·Journal of Cardiovascular Translational Research·Pravin PratapMichael Berlowtiz
Dec 3, 2011·Journal of Cardiovascular Translational Research·Gabriele PesariniFlavio Ribichini
Apr 16, 2011·Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·N J BreetJ M Ten Berg
Apr 25, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Dominick J Angiolillo, José Luis Ferreiro
Aug 21, 2013·Best Practice & Research. Clinical Haematology·Nick van EsMichiel Coppens
Aug 19, 2008·Lancet·Jean-Pierre Bassand, Christian Hamm
Jul 1, 2006·Nature Clinical Practice. Cardiovascular Medicine·Sam Schulman
Jul 29, 2006·Nature Clinical Practice. Cardiovascular Medicine·Martial Hamon
Aug 26, 2006·Nature Clinical Practice. Cardiovascular Medicine·Lori-Ann Linkins, Jeffrey I Weitz
Aug 26, 2006·Nature Clinical Practice. Cardiovascular Medicine·James J Ferguson, Gary M Idelchik
Feb 20, 2008·Nature Clinical Practice. Cardiovascular Medicine·Elliott M Antman
Jun 30, 2006·The New England Journal of Medicine·Douglas D DeCarolis
Jun 30, 2006·The New England Journal of Medicine·David T Majure, Scott K Aberegg
Aug 28, 2009·The New England Journal of Medicine·Peter DammanRobbert de Winter
Mar 16, 2006·The New England Journal of Medicine·Raymond J Gibbons, Valentin Fuster
Nov 6, 2007·The New England Journal of Medicine·Deepak L Bhatt
May 24, 2008·The New England Journal of Medicine·David A Morrow
Nov 25, 2006·The New England Journal of Medicine·Gregg W StoneUNKNOWN ACUITY Investigators
May 22, 2009·The New England Journal of Medicine·Shamir R MehtaUNKNOWN TIMACS Investigators
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén
Sep 24, 2010·The New England Journal of Medicine·Hervé DecoususUNKNOWN CALISTO Study Group
Aug 21, 2008·European Heart Journal·Andrzej BudajUNKNOWN OASIS 5 Investigators
Oct 15, 2009·European Heart Journal·Jean-Pierre BassandUNKNOWN OASIS 5 and OASIS 6 Investigators

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.